Multi-capsule using cell membrane with excellent skin permeability and cosmetic composition containing same

Abstract

The present invention relates to a multi-capsule using cell membranes and a cosmetic composition containing same. The present invention provides a multi-capsule that is prepared by utilizing actual cell membranes derived from microbial cells or plant cells and mixing a cationic inner capsule and which is biocompatible and exhibits excellent encapsulation efficiency through ionic bonding, and superior elasticity, thus achieving outstanding skin permeability and delivery capability of the encapsulated target substance (active ingredient). In addition, the present invention provides a cosmetic composition containing same, which is biocompatible and exhibits excellent skin delivery ability of a substance to be captured (active ingredient).

Description

Multi-capsules using cell membranes with excellent skin permeability and cosmetic compositions containing the same

[0001] The present invention relates to a multi-capsule using a cell membrane with excellent skin permeability and a cosmetic composition containing the same, and more particularly, to a method for manufacturing a multi-capsule using an actual cell membrane and through ionic bonding, and to a cosmetic composition containing the same with excellent skin permeability and delivery ability.

[0002] The skin functions as a protection, barrier, temperature regulation, excretion, and respiration. It is composed of the epidermis, the outermost layer and primary protective barrier; the dermis, which moisturizes and protects the skin; and the subcutaneous fat, which supplies nutrients and absorbs shock. To effectively impart these functional benefits to the skin, there is a growing need for materials with superior skin permeability and delivery.

[0003] Meanwhile, liposomes are vesicles composed of phospholipids present in biological membranes. They are liquid crystalline structures in aqueous solutions, capable of simultaneously entrapping hydrophilic and lipophilic components within their structure. Because of their excellent biosynthesis and biodegradability, they are widely used as a technology to deliver target substances (active ingredients) in various fields such as cosmetics, food, and pharmaceuticals. However, they are highly sensitive to the external environment, and the target substances (active ingredients) inside the liposomes may not be stabilized and may leak out. Therefore, research is also needed on technologies that can stably deliver substances.

[0004] Meanwhile, since these liposomes are artificially synthesized lipids, delivery systems utilizing natural cell membranes are also being developed. Related technologies include Korean Patent No. 10-1720851, which describes nanovesicles made using mammalian cell-derived lipid membranes, and Korean Patent Publication No. 10-2023-0144472, which describes lipid nanoparticles made using animal macrophage membranes.

[0005] The present invention aims to develop and provide a multi-capsule that utilizes an actual cell membrane, is biocompatible, has excellent capture efficiency through ionic bonding, and has excellent elasticity, thereby providing excellent skin penetration and delivery of captured capture target substances (active ingredients), and thereby aims to provide a cosmetic composition that is biocompatible and has excellent skin delivery of capture target substances (active ingredients).

[0006] The present invention provides a cell membrane multi-capsule, which is formed by using a glycolipid as a capsule structural material and a cationic emulsifier positioned between the glycolipids, and is surrounded by a glycolipid mixed with a cell membrane lysate, so that the cationic capsule is enclosed within the glycolipid mixed with the cell membrane lysate.

[0007] Meanwhile, in the present invention, the cationic capsule may preferably have a substance to be captured captured.

[0008] Meanwhile, in the present invention, the cell membrane multi-capsule may preferably be one in which a plurality of 'cationic capsules' are contained within a 'glycolipid mixed with cell membrane lysate'.

[0009] Meanwhile, in the present invention, the cell membrane lysate may preferably be a lysate of a plant or microbial cell membrane.

[0010] Meanwhile, in the present invention, the cell membrane lysate may be obtained by dismantling the cell membrane structure, preferably through hydrolysis.

[0011] Meanwhile, in the present invention, the 'cell membrane lysate-mixed glycolipid' is preferably prepared by mixing cell membrane lysate, an emulsifier, a polyol, and a glycolipid, and the 'cationic capsule' may be prepared by mixing a cationic emulsifier, a polyol, a glycolipid, and a polyglyceryl emulsifier to prepare an oil phase, and then adding an aqueous phase.

[0012] Meanwhile, in the present invention, the oil phase may preferably be one in which a capture target substance is additionally mixed.

[0013] Meanwhile, in the present invention, the emulsifier containing the 'glycolipid mixed with cell membrane lysate' may preferably be an anionic emulsifier.

[0014] In addition, the present invention provides a cosmetic composition characterized by including the cell membrane multi-capsule.

[0015] The present invention utilizes actual cell membranes derived from microbial or plant cells and mixes cationic inner capsules to produce multi-capsules, which are biocompatible, have high capture efficiency through ionic bonding, and have excellent elasticity, thereby providing multi-capsules with excellent skin penetration and delivery of captured capture target substances (active ingredients). In addition, a cosmetic composition containing the same can be provided that is biocompatible and has excellent skin delivery of capture target substances (active ingredients).

[0016] Figure 1 shows a schematic diagram of the manufacture of cationic inner capsules.

[0017] Figure 2 is a schematic diagram of the manufacturing process of a cell membrane multi-capsule manufactured by injecting a cationic inner capsule into a ‘glycolipid mixed with cell membrane lysate.’

[0018] Figure 3 shows the final configuration of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) or plant cells (Olive) as the cell membrane.

[0019] Figure 4 shows the final configuration of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cell, Bifidobacterium) or yeast (eukaryotic cell, Saccharomyces) as the cell membrane.

[0020] Figure 5 is a graph showing the results of analyzing the zeta potential of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) or plant cells (Olive) as the cell membrane.

[0021] Figure 6 is a graph showing the results of analyzing the zeta potential of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cell, Bifidobacterium) or yeast (eukaryotic cell, Saccharomyces) as the cell membrane.

[0022] Figure 7 is a photograph showing the particle morphology of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) or plant cells (Olive) as the cell membrane according to the content of anionic emulsifier.

[0023] Figure 8 is a graph showing the results of analyzing the capture efficiency of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) or plant cells (Olive) as the cell membrane.

[0024] Figure 9 is a graph showing the results of analyzing the antioxidant capacity of the encapsulated material of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) or plant cells (Olive) as the cell membrane.

[0025] Fig. 10 is a graph showing the results of confirming the elasticity of the cell membrane multi-capsule of the present invention using bacteria (prokaryotic cells, Micrococcus) as the cell membrane (Fig. 10a: Example 1-4, Fig. 10b: Example 1-5, Fig. 10c: Example 1-6).

[0026] Fig. 11 is a graph showing the results of confirming the elasticity of the cell membrane multi-capsule of the present invention using plant cells (Olive) as the cell membrane (Fig. 11a: Example 2-4, Fig. 11b: Example 2-5, Fig. 11c: Example 2-6).

[0027] Figure 12 is a graph showing the results of evaluating the skin absorption (absorption rate, speed, depth) efficacy of the cell membrane multi-capsule of the present invention using plant cells (Olive) as the cell membrane.

[0028] Liposomes have been widely used as a technology to deliver capture targets (active ingredients) in the cosmetics, food, and pharmaceutical industries. However, since liposomes are very sensitive to the external environment, the capture targets (active ingredients) inside the liposomes may not be stabilized and may leak out. Therefore, research is needed on technologies that can stably deliver substances. Meanwhile, since these liposomes are artificially synthesized lipids, delivery systems utilizing natural cell membranes have also been developed recently. Therefore, in the present invention, a novel multi-capsule with excellent capture efficiency was developed by utilizing cell membranes derived from microbial or plant cells and applying a multi-capsule capture technique through ionic bonding.

[0029] Accordingly, the present invention provides a cell membrane multi-capsule, which is formed by using a glycolipid as a capsule structural material and a cationic emulsifier positioned between the glycolipids, and is surrounded by a glycolipid mixed with a cell membrane lysate, so that the cationic capsule is enclosed within the glycolipid mixed with the cell membrane lysate.

[0030] Glycolipid refers to a carbohydrate of monosaccharide or polysaccharide bound to lipid by glycosidic bond, and in the present invention, glycolipid was used as a component of the cell membrane multi-capsule.

[0031] Meanwhile, the cationic emulsifier was added to express the cationic polarity of the inner capsule, and is not limited to any known in the art, but as an example, distearoylisopropyl dimonium methosulfate was used in the present invention. In addition, it is preferable to use the cationic emulsifier in an amount of 0.01 to 1 wt%, and more preferably, it is preferable to use 0.3 wt%.

[0032] Meanwhile, the cationic capsule is preferably manufactured using a cationic emulsifier and a polyol, polyglyceryl emulsifier, etc. other than glycolipids, and it is preferably used in an amount of 0.01 to 10 wt% each of the polyol and polyglyceryl emulsifier. In addition, it is preferably used as the polyol, isopentyldiol, or glycerin.

[0033] Meanwhile, in the present invention, the cationic capsule may preferably have a substance to be captured. At this time, the substance to be captured is not limited to any ingredient known in the art as a component that can be captured within the capsule. As an example, the present invention used Ruscogenin, an antioxidant substance. By observing the antioxidant activity of the completed multi-capsule, it was confirmed that as the capture efficiency increased, the substance to be captured was captured and the antioxidant activity did not leak out of the capsule, resulting in a decrease in antioxidant activity. In the present invention, the substance to be captured was also described as an active ingredient.

[0034] Meanwhile, in the present invention, it is preferable to add a preservative to the cationic capsule, and this is not limited to any preservative known in the art.

[0035] Meanwhile, in the present invention, the cell membrane multi-capsule may preferably be one in which a plurality of 'cationic capsules' are contained within a 'glycolipid mixed with cell membrane lysate'.

[0036] Meanwhile, in the present invention, the cell membrane lysate is not limited to any cell derived from a known cell in the art, and for example, plant cells or microbial cells are used. At this time, Olea Europaea (Olive) (preferably leaf extract) was used as a representative plant cell. In addition, microbial cells are usually divided into prokaryotic cells and eukaryotic cells, and in the present invention, Micrococcus and Bifidobacterium were used as representatives of prokaryotic cells, and yeast Saccharomyces was used as a representative of eukaryotic cells. When the above-mentioned cell origins were used as examples, it was confirmed that all multi-capsules were well formed, and through this, it was confirmed that the multi-capsule formation of the present invention is not limited to a specific cell.

[0037] Meanwhile, the cell membrane may be a membrane of a plant cell extracted by hydrolysis, or may be obtained from a microbial cell dissolved by hydrolysis or acid hydrolysis, and preferably may be obtained by dismantling the cell membrane structure through hydrolysis. More preferably, an olive leaf extract (Olea Europaea (Olive) Leaf Extract) hydrolyzed and extracted as a cell membrane, or a Micrococcus lysate, a Bifidobacterium lysate, or a Saccharomyces lysate treated by hydrolysis dissolution is used, and these are not limited to any microbial cell or plant cell known in the art.

[0038] Meanwhile, in the present invention, the 'cationic capsule' may be manufactured by mixing a cationic emulsifier, a polyol, a glycolipid, and a polyglyceryl emulsifier to manufacture an oil phase, and adding an aqueous phase. In addition to the cationic emulsifier, an amphoteric emulsifier such as an amino acid series emulsifier may be used by making it cationic according to a specific pH. In addition, the 'glycolipid mixed with cell membrane lysate' may be preferably manufactured by mixing a cell membrane lysate, an emulsifier, a polyol, and a glycolipid.

[0039] Meanwhile, the above-mentioned water is not limited to any known in the art, but examples thereof include purified water, glycerin, hydrogenated lecithin, cetearyl olivate, sodium citrate, citric acid, betaine, etc., and it is preferable to use purified water.

[0040] Meanwhile, in the present invention, the oil phase may preferably further contain a substance to be captured. At this time, the substance to be captured may be any ingredient known in the art that can be captured within the capsule, and is not limited thereto. Examples thereof include vitamin B group such as madecassoside, asiaticoside, ascorbic acid and its derivatives, collagen, hyaluronic acid, panthenol, other vitamins, polyphenols, terpenes, essential oils, organic acids, etc.

[0041] Meanwhile, in the present invention, the emulsifier containing the 'cell membrane lysate-mixed glycolipid' may preferably be an anionic emulsifier. Any emulsifier known in the art is not limited thereto, but as an example, glyceryl citrate / lactate / linoleate / oleate was used in the present invention. In addition, in addition to the anionic emulsifier, an amphoteric emulsifier such as an amino acid series emulsifier may be used by making it anionic depending on a specific pH.

[0042] Meanwhile, the cell membrane multi-capsule of the present invention is preferably manufactured by mixing the 'cationic capsule' and the 'glycolipid mixed with cell membrane lysate' at a ratio of about 1:9.

[0043] In addition, the present invention provides a cosmetic composition characterized by including the cell membrane multi-capsule.

[0044] Meanwhile, in the present invention, the cosmetic composition may be, for example, any one selected from among a solution, a suspension, an emulsion, a paste, a toner, a gel, a water-soluble liquid, a cream, an essence, a surfactant-containing cleanser, an oil, an oil-in-water (O / W) type, and a water-in-oil (W / O) type; a skin; a lotion; an eye cream; a soothing gel; an ointment; a mask pack type; a body wash type; a peeling gel; an oil-in-water type and a water-in-oil type makeup base; a foundation; a skin cover; a lipstick, a lip gloss, a face powder, a two-way cake, an eye shadow, a cheek color, and an eyebrow pencil; a scalp type; and preferably, at least one formulation selected from the group consisting of a transparent skin toner, a transparent essence, a low-viscosity emulsified lotion essence, and a high-viscosity emulsified cream.

[0045] In addition, the cosmetic composition of the present invention may contain adjuvants commonly used in the cosmetic field, such as hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, deodorants, dyes, etc. The amounts of these various adjuvants are amounts commonly used in the field, and in any case, the adjuvants and their proportions will be selected so as not to adversely affect the desirable properties of the cosmetic composition according to the present invention.

[0046] Additionally, the cosmetic composition of the present invention may be used in conjunction with other cosmetic compositions. Furthermore, the cosmetic composition of the present invention may be used according to conventional usage methods, and the frequency of use may vary depending on the user's skin condition or preference.

[0047] In addition, the present invention provides a method for producing a cell membrane multi-capsule, characterized in that a 'cationic capsule' and a 'glycolipid mixed with cell membrane lysate' are mixed, wherein the 'cationic capsule' is produced by mixing a cationic emulsifier, a polyol, a glycolipid, and a polyglyceryl emulsifier to produce an oil phase and adding an aqueous phase, and the 'glycolipid mixed with cell membrane lysate' is produced by mixing a cell membrane lysate, an emulsifier, a polyol, and a glycolipid. At this time, in manufacturing the cell membrane multi-capsule of the present invention, the 'cationic capsule' and the 'glycolipid mixed with cell membrane lysate' are used, and the order of the steps in manufacturing them can be changed, and preferably, they can be manufactured in the same steps as above (manufacturing the 'cationic capsule', manufacturing the 'glycolipid mixed with cell membrane lysate', and mixing them to manufacture the 'cell membrane multi-capsule').

[0048] Meanwhile, in the manufacturing method of the present invention, when manufacturing a 'cationic capsule', a capsule is formed even if mixing is performed at the level of hand-mixing, but preferably, the completeness of the capsule can be further improved by using a homogenizer to make it homogeneous.

[0049] Meanwhile, in the manufacturing method of the present invention, a capture target substance may be additionally mixed in the oil phase.

[0050] Meanwhile, according to the following experiment, it was confirmed that the cell membrane multi-capsules manufactured by mixing cationic capsules into the 'glycolipid mixed with cell membrane lysate' of the present invention captured well both microbial cells and plant cells, and as the content of the anionic emulsifier increased, the zeta potential value decreased, which increased the capture efficiency, and thus the cell membrane multi-capsules that captured the capture target substance (active ingredient) well could be better formed. The formation of the cell membrane multi-capsules of the present invention was not limited to specific cells, and the multi-capsules could be well formed even when capturing the active ingredient. In addition, they have high elasticity and can easily penetrate through nanofilters, so they have excellent skin penetration and delivery ability.

[0051] Accordingly, the multi-capsules manufactured by the above-described manufacturing method and the cosmetic composition containing the same are biocompatible, have a very high capture efficiency through ionic bonding, have good elasticity, and thus have high skin penetration and delivery ability, and can excellently exhibit the skin delivery ability of the capture target substance (active ingredient), and are expected to be applicable as materials for various cosmetic compositions.

[0052]

[0053] Hereinafter, the present invention will be described in more detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, but includes modifications of technical concepts equivalent thereto.

[0054]

[0055] [Examples 1 to 4: Manufacturing of multiple capsules using the cell membrane of the present invention]

[0056] In this example, we attempted to manufacture multiple capsules using cell membranes.

[0057] First, cationic emulsifier, polyol, glycolipid, and polyglyceryl emulsifier were well mixed, and after self-arrangement, an aqueous phase was added to float the capsules, thereby producing a ‘cationic inner capsule’ (Fig. 1, Active Encapsulated Vesicle (CV, hereinafter referred to as CV): cationic inner capsule containing an active substance, Blank Vesicle (BV, hereinafter referred to as BV): cationic inner capsule without an active substance). In addition to the cationic emulsifier, lipids such as polyol (Isopentyldiol, Glycerine), glycolipid (Jojoba Ester, Glycolipid, Phytosphingosine), and polyglyceryl-4 Laurate were used. At this time, capsules were formed even if hand-mixing was performed, but the completeness of the capsules was further improved when homogenized using a homogenizer. The specific composition was as shown in Table 1 below.

[0058] Composition of cationic inner capsule Phase Ingredient Chemical BVCVA Cationic emulsifier Distearoylisopropyl Dimonium Methosulfate a 0.30.3A Polyglyceryl Emulsifier Polyglyceryl-4 Laurate 55A Glycolipid Jojoba Ester 0.30.3A Glycolipid Glycolipid 0.30.3A Glycolipid Phytosphingosine 0.01 0.01A Polyol Isopentyldiol 55A Polyol Glycerine 10 10A Target Material Ruscogenin b00.1BWater77.5977.49BPreservative1.51.5

[0059] a : Used as a cationic emulsifier.

[0060] b : It is an antioxidant substance used as a capture target substance (active ingredient).

[0061]

[0062] Next, lipids were recombined using four types of cell membranes (hydrolysis-dissolved bacterial (Micrococcus), hydrolysis-extracted plant cell membrane (Olive), hydrolysis-dissolved Bifidobacterium strain, and hydrolysis-dissolved Saccharomyces yeast), and each cell membrane lysate, emulsifier, polyol (Isopentyldiol), and glycolipid were mixed to recombinantly form 'cell membrane lysate-mixed glycolipid'. The specific compositions were as shown in Tables 2 to 5 below.

[0063] Glycolipid cell membrane lysate using bacterial (prokaryotic) lysate Glycolipid polyol emulsifier Sample Micrococcus Lysate a GlycolipidIsopentyldiolGlyceryl Citrate / Lactate / Linoleate / Oleate b BV-DM34300.2A·BV-DM3430.20.5A·BV-DM3430.5CV-DM34300.2A·CV-DM3430.20.5A·CV-DM3430.5

[0064] a : An example of a bacterial (prokaryotic) lysate.

[0065] b : Used as an anionic emulsifier.

[0066] DM: Drained Bacterial Membrane (hereinafter referred to as DM).

[0067] A: Anionic Surfactant.

[0068] Glycolipid cell membrane lysate using plant cell lysate Glycolipid polyol emulsifier Sample Olea europaea (Olive) Leaf Extract a GlycolipidIsopentyldiolGlyceryl Citrate / Lactate / Linoleate / Oleate b BV-OM34300.2A·BV-OM3430.20.5A·BV-OM3430.5CV-OM34300.2A·CV-OM3430.20.5A·CV-OM3430.5

[0069] a : An example of plant cell lysate.

[0070] b : Used as an anionic emulsifier.

[0071] OM: Olive Membrane (hereinafter referred to as OM).

[0072] A: Anionic Surfactant.

[0073] Glycolipid cell membrane lysate using bacterial (prokaryotic) lysate Glycolipid polyol emulsifier Sample Bifida Ferment Lysate a GlycolipidIsopentyldiolGlyceryl Citrate / Lactate / Linoleate / Oleate b X3430X 0.23430.2X 0.53430.5

[0074] a : An example of a bacterial (prokaryotic) lysate.

[0075] b : Used as an anionic emulsifier.

[0076] Saccharomyces Ferment Lysate-based Glycolipid Cell Membrane Lysate Glycolipid Polyol Emulsifier Sample a GlycolipidIsopentyldiolGlyceryl Citrate / Lactate / Linoleate / Oleate b M3430M 0.23430.2M 0.53430.5

[0077] a : An example of a yeast (eukaryotic cell) lysate.

[0078] b : Used as an anionic emulsifier.

[0079]

[0080] Afterwards, the cationic inner capsule was added to the recombinant 'cell membrane lysate-mixed glycolipid' and mixed to complete the cell membrane multi-capsule (Fig. 2), which was manufactured by mixing the 'cell membrane lysate-mixed glycolipid' and the cationic capsule at a ratio of about 1:9. The final composition is as shown in Fig. 3 (Examples 1-1 to 1-6, Examples 2-1 to 2-6) and Fig. 4 (Examples 3-1 to 3-3, Examples 4-1 to 4-3), and first, the anionic base (glycolipid) was manufactured (ex. 3:4:3:0.5, a lipid base was manufactured by mixing 3 g, 4 g, 3 g, and 0.5 g), and the anionic base and the cationic capsule base were mixed at a ratio of about 1:9, respectively. The final experiment was performed using this below.

[0081]

[0082] [Experimental Example 1: Confirmation of the zeta potential of the cell membrane multi-capsule of the present invention]

[0083] In this experimental example, the zeta potential of the cell membrane multi-capsules of the above examples was confirmed. The degree of capsule formation was determined by measuring the zeta potential according to the treatment group that increased the content of anionic emulsifier. As a result, as shown in Fig. 5, the zeta potential of the cell membrane multi-capsules of Examples 1-1 to 1-6 using bacteria (prokaryotic cells, Micrococcus) as the cell membrane and Examples 2-1 to 2-6 using plant cells was analyzed. As a result, as shown in Fig. 5, it was confirmed that the zeta potential value of all treatment groups decreased as the content of anionic emulsifier increased, and the zeta potential values ​​of the treatment group (DM) using bacteria (prokaryotic cells, Micrococcus) were lower than those of the treatment group (OM) using plant cells.

[0084] In addition, as shown in Fig. 6, the zeta potential of the cell membrane multi-capsules of Examples 3-1 to 3-3 using bacteria (prokaryotic cells, Bifidobacterium) as the cell membrane and Examples 4-1 to 4-3 using yeast (eukaryotic cells, Saccharomyces) was analyzed, and as a result, the zeta potential value decreased as the anionic emulsifier content increased, and the main size peak showed a tendency to shift to the left. This is thought to be because the encapsulation progressed further and the particle distribution tended to lean toward the smaller side. In summary, it was found that more cationic capsules were captured inside the multi-capsules, and thus the + value decreased, and it was found that multi-capsules were well formed regardless of the type of cell membrane used, and it was found that multi-capsules were well formed even when capturing active ingredients. Accordingly, in the following experiments, additional experiments were conducted using Examples 1-1 to 1-6 using bacteria (prokaryotic cells, Micrococcus) as representative cell membranes, and Examples 2-1 to 2-6 using plant cells.

[0085]

[0086] [Experimental Example 2: Observation of particle morphology of the cell membrane multi-capsule of the present invention]

[0087] In this experimental example, the particle morphology of the cell membrane multi-capsules of the above examples was observed according to the content of anionic emulsifier. For example, bacterial (prokaryotic cell, Micrococcus) and plant cells were used as cell membranes, respectively, and the particle morphology of cell membrane multi-capsules without active ingredients was observed.

[0088] The particle morphology according to the content of anionic surfactant was observed using a transmission electron microscope (TEM), and as a result, it was confirmed that encapsulation was achieved even without using anionic surfactant, as shown in Fig. 7. However, as the content of anionic surfactant increased, it was confirmed that the internal capsules became more dense and had a solid shape. In addition, this tendency was observed equally in the treatment group using bacteria (prokaryotic cells) (DM) as well as the treatment group using plant cells (OM).

[0089]

[0090] [Experimental Example 3: Confirmation of the capture efficiency of the cell membrane multi-capsule of the present invention and the antioxidant capacity of the capture material]

[0091] In this experimental example, the capture efficiency of the cell membrane multi-capsules that captured the capture target substance (active ingredient) of the above example and the antioxidant activity of the captured substance were confirmed. As an example, cell membrane multi-capsules using bacteria (prokaryotic cells, Micrococcus) and plant cells, respectively, as cell membranes were used.

[0092] First, the capture efficiency of the fabricated cell membrane multi-capsules containing the capture target substance (active ingredient) was observed. This was done by adding a fluorescent substance to the internal phase of the cationic inner capsule and comparing and measuring the concentration in the external phase of the final multi-capsule. As a result, as shown in Fig. 8, the fabricated cell membrane multi-capsules containing the capture target substance (active ingredient) had a capture efficiency of over 82% even without using anionic emulsifiers, and it was confirmed that the capture efficiency increased as the anionic emulsifier content increased. This tendency was observed in both the treatment group using bacteria (prokaryotic cells) (DM) and the treatment group using plant cells (OM). In addition, the treatment group using bacteria (prokaryotic cells) (DM) had a higher capture efficiency than the treatment group using plant cells (OM), which practically confirmed that a low zeta potential value in the above results indicates a high capture efficiency.

[0093] As evidence of this, the antioxidant capacity of the capture target substance (active ingredient) compared to Vit C was measured, and as shown in Fig. 9, it was confirmed that as the capture efficiency increased, the antioxidant capacity decreased in line with the capture efficiency trend. This can be judged to mean that the active ingredient was captured and the antioxidant capacity did not leak out of the capsule. Therefore, in conclusion, as the content of anionic emulsifier increases, the capture efficiency increases (i.e., it is captured better), which means that multi-capsules are formed better.

[0094]

[0095] [Experimental Example 4: Confirmation of the elasticity of the cell membrane multi-capsule of the present invention]

[0096] In this experimental example, the elasticity of the cell membrane multi-capsules containing the target substance (active ingredient) of the above example was examined. These were passed through a millipore filter and the particle distribution and size changes were observed. As an example, cell membrane multi-capsules using bacterial (prokaryotic cell, Micrococcus) and plant cells, respectively, as cell membranes were used.

[0097] The elasticity of vesicles is a representative characteristic that has the effect of allowing passage through narrow passages (e.g., stratum corneum), and thus greatly improves skin penetration and delivery ability. Accordingly, the distribution of the manufactured cell membrane multi-capsules including the capture target substance (active ingredient) was analyzed using a particle size analyzer, and then the multi-capsules were passed through a 100 nm millipore filter to measure the change in the distribution and whether vesicles with a size of 100 nm or more were passed through. As a result, as shown in Figs. 10 and 11, it was confirmed that all treatment groups had very similar particle distributions before and after penetration, and vesicles with a size of 100 nm or more were maintained. Accordingly, it was found that the cell membrane multi-capsules of the present invention have excellent elasticity and superior skin penetration and delivery ability.

[0098]

[0099] [Experimental Example 5: Clinical test of skin penetration of the cell membrane multi-capsule of the present invention]

[0100] In this experimental example, a skin permeation clinical test was conducted on a cell membrane multi-capsule containing the target substance (active ingredient) of the above example to determine whether it truly exhibits superior skin delivery ability. As an example, a cell membrane multi-capsule using plant cells as the cell membrane was used.

[0101] The efficacy of skin absorption (absorption rate, speed, depth) was evaluated using 3D Raman Spectroscopy. The clinical recruits were healthy Korean men and women aged 19 years or older without any acute or chronic physical diseases including skin diseases, and the test was conducted on 20 subjects. As a result, as shown in Fig. 12, the skin absorption amount (AU) of the forearm area significantly increased after one use compared to before use of the capsule (p<0.05). In addition, the skin absorption rate (um / h) and skin absorption depth (um) also significantly increased (p<0.05). Therefore, it was confirmed that the cell membrane multi-capsule of the present invention has excellent skin penetration.

[0102]

[0103] In summary, the present invention uses a recombinant 'cell membrane lysate-mixed glycolipid' using actual cell membranes (microbial cells, plant cells) and cationic capsules to produce cell membrane multi-capsules having excellent capture efficiency and elasticity through ionic bonding, and excellent skin penetration and delivery of the captured capture target substance (active ingredient). In addition, by using an anionic emulsifier together, the zeta potential value decreases as the content increases, resulting in a high capture efficiency, enabling better formation of multi-capsules. This was proven by the fact that multi-capsules capturing capture target substances (active ingredients) actually exhibit high capture efficiency. Therefore, the cell membrane multi-capsules of the present invention can be utilized as a cosmetic composition that is biocompatible and has excellent skin delivery ability of capture target substances (active ingredients).

Claims

1. A cell membrane multi-capsule formed by using glycolipids as a capsule structural material and positioning a cationic emulsifier between the glycolipids, and surrounding the 'glycolipids mixed with cell membrane lysates', so that the 'cationic capsules' are enclosed within the 'glycolipids mixed with cell membrane lysates'.

2. In paragraph 1, In the above cationic capsule, A cell membrane multi-capsule characterized by having a target substance captured therein.

3. In paragraph 1, The above cell membrane multi-capsules are, A cell membrane multi-capsule characterized in that a plurality of 'cationic capsules' are contained within a 'glycolipid mixed with cell membrane lysate'.

4. In paragraph 1, The above 'cell membrane lysate' is, A cell membrane multi-capsule characterized by being a lysate of a plant or microbial cell membrane.

5. In paragraph 1 or paragraph 4, The above 'cell membrane lysate' is, A cell membrane multi-capsule characterized in that it is obtained by dismantling the cell membrane structure through hydrolysis.

6. In paragraph 1, The above 'cationic capsule' is manufactured by mixing a cationic emulsifier, polyol, glycolipid, and polyglyceryl emulsifier to prepare an oil phase and adding an aqueous phase. The above 'glycolipid mixed with cell membrane lysate' is, A cell membrane multi-capsule characterized by being manufactured by mixing cell membrane lysate, emulsifier, polyol, and glycolipid.

7. In paragraph 6, The above fee is, A cell membrane multi-capsule characterized by having an additional mixture of a capture target substance.

8. In paragraph 6, The emulsifier mixed with the above 'cell membrane lysate-mixed glycolipid' is A cell membrane multi-capsule characterized by being an anionic emulsifier.

9. A cosmetic composition characterized by comprising the cell membrane multi-capsule of paragraph 1.

Images